Bristol-Myers Squibb Co
XMUN:BRM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Bristol-Myers Squibb Co
XMUN:BRM
|
US |
|
E
|
Equinix Inc
SWB:EQN2
|
US |
|
Panasonic Holdings Corp
OTC:PCRFF
|
JP |
|
H
|
Home Depot Inc
SGO:HD
|
US |
|
Internet Initiative Japan Inc
OTC:IIJIF
|
JP |
Bristol-Myers Squibb Co
Bristol-Myers Squibb is a global drugmaker that develops, manufactures, and sells prescription medicines for serious diseases. Its products are used mainly in cancer, heart disease, immune disorders, and blood diseases. The company spends heavily on research, clinical trials, and regulatory approval because its business depends on turning scientific discoveries into approved medicines. The company earns money by selling branded drugs to hospitals, doctors, pharmacies, and other healthcare providers, which then reach patients through the healthcare system. Some of its best-known products are used by cancer specialists and by doctors treating autoimmune or cardiovascular conditions. It also works with other drug companies through licensing and collaboration deals, which can add milestone payments and royalties. Bristol-Myers Squibb stands out because it is not a broad healthcare company; it is focused on a relatively small number of high-value prescription medicines that require strong medical evidence and tight regulatory control. That gives it a role near the top of the pharmaceutical value chain, where success depends on patent-protected brands, medical trust, and a steady pipeline of new drugs to replace older ones.
Bristol-Myers Squibb is a global drugmaker that develops, manufactures, and sells prescription medicines for serious diseases. Its products are used mainly in cancer, heart disease, immune disorders, and blood diseases. The company spends heavily on research, clinical trials, and regulatory approval because its business depends on turning scientific discoveries into approved medicines.
The company earns money by selling branded drugs to hospitals, doctors, pharmacies, and other healthcare providers, which then reach patients through the healthcare system. Some of its best-known products are used by cancer specialists and by doctors treating autoimmune or cardiovascular conditions. It also works with other drug companies through licensing and collaboration deals, which can add milestone payments and royalties.
Bristol-Myers Squibb stands out because it is not a broad healthcare company; it is focused on a relatively small number of high-value prescription medicines that require strong medical evidence and tight regulatory control. That gives it a role near the top of the pharmaceutical value chain, where success depends on patent-protected brands, medical trust, and a steady pipeline of new drugs to replace older ones.
Solid quarter: Bristol Myers reported first-quarter revenue of about $11.5 billion, up 1% year over year, and said performance was tracking toward the upper end of its full-year guidance ranges.
Growth portfolio: Growth portfolio sales rose 9% to $6.2 billion, led by products like Reblozyl, Breyanzi, Camzyos, Opdualag, Qvantig and Cobenfy.
Pipeline momentum: Management highlighted multiple recent clinical and regulatory wins, including FDA acceptance of iberdomide with breakthrough therapy and priority review, positive mezigdomide data, and positive data for Iza-bren, Sotyktu, Opdivo, Camzyos and Reblozyl.
Late-year catalysts: The company said the back half of 2026 will bring an increasing cadence of pivotal readouts, including milvexian, Cobenfy in Alzheimer’s psychosis, admilparant in IPF, and iberdomide PFS data.
Capital allocation: Bristol Myers reaffirmed full-year 2026 guidance, kept business development as a top priority, and said it still expects to deliver the remaining $2 billion of cost savings from its productivity program by the end of 2027.
Commercial strength: Management pointed to strong demand for Eliquis, Camzyos, Breyanzi and Qvantig, while also noting some near-term inventory timing effects for Eliquis and Opdivo.
Management
Dr. Christopher S. Boerner, Ph.D., is a prominent figure in the pharmaceutical industry, notably serving in key leadership roles at Bristol-Myers Squibb (BMS), a global biopharmaceutical company. With a strong background in health care and a commitment to advancing science, Dr. Boerner has contributed significantly to the development and commercialization of innovative medicines. He holds a Bachelor of Arts in Economics and History from Washington University in St. Louis and a Ph.D. in Marketing from Duke University. Before his tenure at BMS, Dr. Boerner gathered extensive experience in the industry through various positions where he developed a keen insight into the commercial and strategic aspects of pharmaceuticals. At Bristol-Myers Squibb, Dr. Boerner held the position of Executive Vice President and Chief Commercial Officer, where he played a crucial role in leading the company's commercial operations worldwide. His responsibilities included overseeing strategies that drive the growth of BMS’s portfolio and ensuring that patients have access to crucial therapies. Dr. Boerner is also recognized for his leadership and strategic vision in enhancing the company's market presence globally. Under his leadership, BMS has been able to expand its therapeutic reach and strengthen its commercial capabilities, helping the company maintain its competitive edge in the industry. Recognized for his dedication to patients and innovation, Dr. Boerner continues to influence the field through his work at Bristol-Myers Squibb.
He holds a Bachelor of Arts in Economics and History from Washington University in St. Louis and a Ph.D. in Marketing from Duke University. Before his tenure at BMS, Dr. Boerner gathered extensive experience in the industry through various positions where he developed a keen insight into the commercial and strategic aspects of pharmaceuticals.
At Bristol-Myers Squibb, Dr. Boerner held the position of Executive Vice President and Chief Commercial Officer, where he played a crucial role in leading the company's commercial operations worldwide. His responsibilities included overseeing strategies that drive the growth of BMS’s portfolio and ensuring that patients have access to crucial therapies. Dr. Boerner is also recognized for his leadership and strategic vision in enhancing the company's market presence globally.
Under his leadership, BMS has been able to expand its therapeutic reach and strengthen its commercial capabilities, helping the company maintain its competitive edge in the industry. Recognized for his dedication to patients and innovation, Dr. Boerner continues to influence the field through his work at Bristol-Myers Squibb.
David V. Elkins is a well-regarded figure in the pharmaceutical industry, known for his expertise in financial management and leadership. As of his recent roles, he serves as the Executive Vice President and Chief Financial Officer (CFO) of Bristol-Myers Squibb, a leading global pharmaceutical company. Elkins joined Bristol-Myers Squibb in 2019, bringing with him a wealth of experience in corporate finance and strategic planning. Before his tenure at Bristol-Myers Squibb, Elkins held several significant positions, including CFO roles at various prestigious companies. He was the CFO for the Diagnostics and Life Sciences segments at Danaher Corporation. Prior to Danaher, he gained extensive experience at AstraZeneca, where he took on multiple leadership roles over his 19-year career there. Elkins' expertise spans financial strategy, capital markets, and risk management. His leadership at Bristol-Myers Squibb focuses on driving financial excellence, supporting business growth, and enhancing shareholder value through strategic financial planning and execution. His educational background includes an MBA, which further supports his adeptness in managing complex financial operations and guiding corporate strategies in the highly competitive pharmaceutical industry.
Before his tenure at Bristol-Myers Squibb, Elkins held several significant positions, including CFO roles at various prestigious companies. He was the CFO for the Diagnostics and Life Sciences segments at Danaher Corporation. Prior to Danaher, he gained extensive experience at AstraZeneca, where he took on multiple leadership roles over his 19-year career there. Elkins' expertise spans financial strategy, capital markets, and risk management.
His leadership at Bristol-Myers Squibb focuses on driving financial excellence, supporting business growth, and enhancing shareholder value through strategic financial planning and execution. His educational background includes an MBA, which further supports his adeptness in managing complex financial operations and guiding corporate strategies in the highly competitive pharmaceutical industry.
Sandra Leung is a prominent legal executive known for her role at Bristol-Myers Squibb Co., where she has served as the General Counsel. She joined the company in 1992 and has held various significant positions. Before transitioning to her role in corporate law, she was an Assistant District Attorney in the New York County District Attorney's Office. At Bristol-Myers Squibb, Leung has been instrumental in overseeing legal matters, advising on corporate strategy, and managing the company’s legal risks. Her leadership has been critical in navigating complex legal landscapes, regulatory challenges, mergers, and acquisitions. Additionally, she has been a strong advocate for diversity and inclusion within the legal profession and the broader business community.
Dr. Samit Hirawat is a prominent figure in the pharmaceutical industry, serving as the Executive Vice President and Chief Medical Officer, Global Drug Development, at Bristol-Myers Squibb Co. He is responsible for advancing the company's clinical development pipeline across oncology, hematology, immunology, and cardiovascular therapy areas. Dr. Hirawat brings extensive experience in drug development and a strong track record of bringing innovative therapies to market. Before joining Bristol-Myers Squibb, Dr. Hirawat held several key positions at Novartis, where he was instrumental in developing and obtaining regulatory approval for multiple critical cancer therapies. His expertise spans clinical research, regulatory affairs, and strategic development, focusing on precision medicine and patient-centric approaches. Dr. Hirawat earned his M.D. from the University of Rajasthan in India and completed his clinical training in internal medicine and oncology. He is known for his commitment to leveraging scientific insights to develop transformative medicines that improve patient outcomes globally. His leadership continues to shape Bristol-Myers Squibb's efforts to address unmet medical needs through innovative science.
Before joining Bristol-Myers Squibb, Dr. Hirawat held several key positions at Novartis, where he was instrumental in developing and obtaining regulatory approval for multiple critical cancer therapies. His expertise spans clinical research, regulatory affairs, and strategic development, focusing on precision medicine and patient-centric approaches.
Dr. Hirawat earned his M.D. from the University of Rajasthan in India and completed his clinical training in internal medicine and oncology. He is known for his commitment to leveraging scientific insights to develop transformative medicines that improve patient outcomes globally. His leadership continues to shape Bristol-Myers Squibb's efforts to address unmet medical needs through innovative science.
Greg Meyers is the Executive Vice President and Chief Digital & Technology Officer at Bristol-Myers Squibb Co., a global biopharmaceutical company. In his role, Meyers is responsible for advancing the company's digital capabilities and ensuring that technology plays a central role in accelerating the delivery of life-saving medicines. He oversees digital health initiatives, data analytics, cybersecurity, and information technology strategies. With a rich background in leveraging technology for business transformation, Meyers has been instrumental in driving innovation and efficiency across the company's operations. Before joining Bristol-Myers Squibb, he held various leadership positions focused on IT and digital transformation in other multinational companies, contributing to the integration of emerging technologies into corporate strategies. His work emphasizes enhancing patient outcomes through digital innovation and maintaining the company's competitive edge in the biopharmaceutical industry.
Timothy C. Power is a significant figure associated with Bristol-Myers Squibb Co. He has served in a key legal capacity at the company, notably as the Senior Vice President and Associate General Counsel, Corporate, and Assistant Secretary. In this role, Power has been responsible for overseeing various legal aspects of the company’s global operations, focusing on corporate governance, securities law compliance, and corporate transactions. His expertise has been instrumental in guiding the company's legal strategies and ensuring alignment with its business objectives. Power's leadership and legal acumen have contributed to the strategic decision-making processes at Bristol-Myers Squibb, supporting the company's mission to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases.
Ahn Amanda Poole serves as an executive at Bristol-Myers Squibb Co., a renowned global biopharmaceutical company. In her role, she is deeply involved in the company's strategic operations and initiatives, focusing on delivering innovative medicines for patients battling serious diseases. Her expertise and leadership are instrumental in guiding teams across various functions to achieve the company’s strategic objectives and enhance its competitive positioning in the biopharmaceutical industry. Under her guidance, Bristol-Myers Squibb has continued to strengthen its market presence and commitment to research and development, aiming to make significant advancements in healthcare. Her contributions have been significant in fostering a culture of excellence and innovation within the organization.
Dr. Joseph J. Eiden Jr. is currently not publicly known as a prominent figure associated with Bristol-Myers Squibb Co. Therefore, there is no available biography or detailed information about him in the context of this company. If he has a specific role or contributions, it might not be widely documented in public resources. Please verify the name or provide additional context if you are searching for someone else.
Adam Lenkowsky is a prominent executive at Bristol-Myers Squibb Co., a global biopharmaceutical company. He serves as the Senior Vice President and General Manager of the U.S. Commercial Business, where he plays a crucial role in driving the strategic direction and performance of the company's commercial operations in the United States. With over two decades of experience in the pharmaceutical industry, Lenkowsky has held various leadership positions within the company, contributing his expertise in sales, marketing, and strategic planning. His leadership focuses on enhancing the company's market presence and ensuring access to innovative medicines for patients. Lenkowsky's extensive industry knowledge and commitment to patient care have been instrumental in his contributions to Bristol-Myers Squibb's success.
Catherine E. Owen is a distinguished executive at Bristol-Myers Squibb Co., serving as the Senior Vice President of Major Markets. With a robust background in the pharmaceutical industry, she plays a crucial role in leading and executing the company's strategy across key international markets, enhancing the company's global footprint. Owen joined Bristol-Myers Squibb with extensive experience, having previously held significant leadership positions that have contributed to her expertise in market access, product launches, and strategic operations. Her leadership is characterized by a strong commitment to driving growth and innovation, focusing on patients' needs and expanding access to the company's therapies worldwide. She is widely respected for her ability to navigate the complexities of international markets, her strategic vision, and her dedication to fostering a culture of inclusivity and performance within her teams. Catherine E. Owen's influence at Bristol-Myers Squibb underscores the company's commitment to leadership excellence in the pharmaceutical industry.
Owen joined Bristol-Myers Squibb with extensive experience, having previously held significant leadership positions that have contributed to her expertise in market access, product launches, and strategic operations. Her leadership is characterized by a strong commitment to driving growth and innovation, focusing on patients' needs and expanding access to the company's therapies worldwide.
She is widely respected for her ability to navigate the complexities of international markets, her strategic vision, and her dedication to fostering a culture of inclusivity and performance within her teams. Catherine E. Owen's influence at Bristol-Myers Squibb underscores the company's commitment to leadership excellence in the pharmaceutical industry.
